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L-dopaFirst line treatment for Parkinson’s disease (PD) is typically either L-dopa or a non-ergot dopamine ago-
nist (DA). However, the options for the treatment of motor symptoms in PD patients have increased in the
last thirty years, which have seen several new classes of PD medications introduced onto the market. The
purpose of this study is to examine the changes in first line therapy of newly diagnosed Parkinson’s
patients between 2000 and 2016 in Wales.
A population-based study evaluated data from the Secure Anonymised Information Linkage (SAIL)
Databank of residents in Wales, aged 40 years or older, newly treated with PD medications between
2000 and 2016. The data was compared across three intervals: 2000–2005, 2006–2011 and 2012–
2016. Patients were classified by age at diagnosis into young: 40–60 years; mid, 61–80 years; and older
>80 years. Logistic regression was undertaken to determine the predictors of PD medication prescribing.
For the whole study period, the profiles of 9142 newly diagnosed PD patients were analysed. L-dopa
was the most common first line therapy (80.6%), followed by non-ergot DAs (12.9%) and monoamine oxi-
dase B (MAO-B) inhibitors (7.9%). Odds of L-dopa prescribing were greater in patients >80 years
(OR = 20.46 95%CI: 16.25–25.76) and in the period 2012–2016 (OR = 1.98 95% CI: 1.70–2.29).
Prescribing of non-ergot DAs significantly declined in 2012–2016 (OR = 0.42 95% CI: 0.35–0.49).
Additional factors influencing first line therapy were deprivation, presence of diabetes and prior use of
antidepressants. For example, PD patients residing in the least deprived area were less likely to be pre-
scribed L-dopa compared to patients residing in the most deprived area (OR = 0.77 95% CI: 0.65–0.93).
First line therapy in PD in Wales has undergone a significant switch towards L-dopa over the last
16 years. The data indicates reasonable compliance with guidelines on efficacy and safety issues related
to Parkinson’s medications.
 2021 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Whilst the symptomatic treatment of the neurodegenerative
disorder Parkinson’s disease (PD) used to be restricted to the dopa-
mine precursor L-dopa and anticholinergics, the number and type
of pharmacological agents has increased significantly in the last
thirty years with the introduction of several new classes of PDmedications. These include non-ergot dopamine agonists (DAs),
monoamine oxidase-B (MAO-B) inhibitors and Catechol-O-methyl
transferase (COMT) inhibitors. Knowledge on the efficacy and
safety of each of these has developed through their prescribing
and via post marketing surveillance. For example, the conclusions
of a robust review by the American Academy of Neurology (AAN) in
2006 surmised that DAs, MAO-B inhibitors and L-dopa do not pro-
vide any disease modifying properties (Suchowersky et al., 2006).
DAs were introduced to the practice with the hope of avoiding
the dyskinesia caused by L-dopa. Several clinical trials conducted
between 1989 and 2006 compared L-dopa to different DAs, such
as bromocriptine, ropinirole, pramipexole, and pergolide; these tri-
als concluded that starting a therapy with DAs was associated with
delaying dyskinesia or motor fluctuations or both (Zhang and Tan,
2016). These trials led to guidelines recommending starting ther-
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the motor symptoms (Miyasaki et al., 2002). However, the effect of
dyskinesia and/or the motor fluctuations caused by L-dopa on
quality of life (QOL) was unknown until 2014, when the PD-MED
study showed that the early use of L-dopa in PD patients led to a
better QoL compared to DAs and MAO-B inhibitors in the long term
(Gray et al., 2014).
Whilst such findings should influence clinical prescribing and
decision making, they have fuelled the ongoing debate on the most
appropriate first line therapy for patients newly diagnosed with PD
(Gray et al., 2014). This debate has focussed particularly on the ini-
tiation of L-dopa versus DAs. For individuals whose motor symp-
toms impact on their quality of life (QoL), recent guidance from
the National Institute for Health and Care Excellence (NICE) in
the United Kingdom (UK) recommends commencing L-dopa treat-
ment. In contrast, for individuals whose QoL is not affected by
motor symptoms, L-dopa, MAO-B inhibitors and DAs are recom-
mended (Institute, 2017).
Notwithstanding these guidelines, there is a paucity of litera-
ture on the prescribing and use of PD medications within the UK,
particularly with reference to Wales. A recent study used the UK
Clinical Practice Research Datalink (CPRD) and found a low rate
of L-dopa prescribing, when it was used as an initial therapy
(29%), across the UK between 2004 and 2015 (Kalilani et al.,
2019). This study did not stratify patients by age, sex, years of pre-
scribing, comorbidities, or other patient characteristics. As a conse-
quence, it has not been possible to understand the current
landscape of prescribing in PD and whether this aligns to the evi-
dence base.
In this study, we examined the trends in first line therapy, as
well as the impact of age, sex, social deprivation status, and co-
morbidities, for PD in Wales, over the period 2000–2016.2. Method
2.1. Data source and study cohort
We conducted a retrospective cohort study using the Secure
Anonymised Information Linkage (SAIL) Databank that includes
General Practice (GP) prescribing data for approximately 80% of
the patient population in Wales (Jones et al., 2017). The SAIL Data-
bank links GP prescribing data to a variety of other health and
social care data sources including (but not limited to) patient
demographics, hospital episodes and Welsh Index of Multiple
Deprivation (WIMD) scores (Jones et al., 2017). All studies using
SAIL data need independent Information Governance Review Panel
(IGRP) approval. This study obtained IGRP approval (ref 0507). The
Research Ethics Service has previously confirmed that SAIL projects
using anonymised routinely collected data do not require specific
research ethics committee approval.
Data from the SAIL Databank were retrieved for the Welsh pop-
ulation between 2000 and 2016. PD patients were identified if they
were (1) diagnosed for first time with PD (Read code, 2nd Revision,
Definition ‘F12. . .’, ‘F120.’, ‘F12z.’, and ‘147F.’) and (2) receiving
medication indicated for the treatment of motor symptoms of
Parkinson’s disease after the date of diagnosis (Read code,
‘dq. . .’). We defined 2000 as the initial study year because of
increased quality and consistency of coding and quality of standard
electronic health record (EHR) data after 2000. Exclusion criteria
were: patients with a PD diagnosis prior to 1/1/2000, patients
who were diagnosed under the age of 40, patients diagnosed
within 6-months of their SAIL registration date (to ensure that inci-
dent cases only were included), patients prescribed any PD medi-
cation before the diagnosis date, and patients who were
receiving antipsychotics up to one year before PD diagnosis as207antipsychotics are known to cause extrapyramidal symptoms
which could be erroneously diagnosed as PD (Pringsheim and
Barnes, 2018).
2.2. Identify individual PD medications
Read codes for PD medications in GP data were identified and
classified into six main categories (supplementary data, Appendix
(1)).
First line therapy was defined as the first PD medication(s) pre-
scribed in the 30 days following initial PD diagnosis. Age, sex,
social deprivation status, health board, year of prescribing, comor-
bidities, and previous use of antidepressants were also recorded as
covariates (Aboukarr and Giudice, 2018). (Appendix (2), Supple-
mentary Data).
2.3. Statistical analysis
A series of multilevel logistic regressions were undertaken to
determine the predictors of PD medication prescribing (Sommet
and Morselli, 2017; Lee, 2000). Data were analysed using SPSS
v.24.0, and R-software v3.5.0.
The dependent variables in the analysis were binary and
included the specific medication categories used as first line ther-
apies in PD. All six categories of the PD medications mentioned
were tested, except for COMT inhibitors and amantadine since
their role in the de novo PD patients is limited (Institute, 2017).
Additionally, apomorphine was excluded from non-ergot DAs since
it is a rescue therapy and its pump formula may be delivered in the
hospital with no record in the GP data. As every patient in the SAIL
Databank is registered with a particular GP practice, which in turn
is nested within a particular health board, a series of multilevel
logistic regression models were used. An empty regression model
was run in R 3.5.0 software for every medication category. This
model included the GP data for the practice nested within the
health board as a random effect and the intraclass correlation
(ICC) was calculated for each model based on the results
(Sommet and Morselli, 2017). If the ICC values were less than
10%, a single level logistic regression was run without considering
the random effects of GP data at practice and health board levels
(Lee, 2000). In line with best practice, a confirmatory step was
needed to ensure the validity of the model outcomes. After adding
the dependent variables in the models (as discussed below), the
odd ratios and confidence intervals of the single and multi-level
logistic regression models were compared. It was found that they
were highly similar in all the models and, therefore, the single level
logistic regression was applied.
The first step in building the final regression model was to
determine which independent variables to include in the multi-
variate model. A particular variable was included in the multivari-
ate model if the p value of the Wald test in the univariate model
was 0.20. Based on the outcomes of the univariate analysis, a
multivariate logistic regression, that included the candidate vari-
ables, was performed to understand the relationship between
those variables and the prescribing choice of the first line therapy.
The odds ratio (OR) and confidence intervals were obtained and the
significance level was set at p < 0.05. Any variable that had less
than 5 patients in any group was excluded from the analysis as
per SAIL policy.
2.4. Sensitivity analysis
To assess the robustness of the study outcomes, a sensitivity
analysis that excluded patients with a history of dementia was
conducted. The rationale behind excluding these patients in the
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as dementia with Lewy body (DLB).3. Results
During the study period (2000–2016) and after applying the
exclusion criteria, there were 9142 newly diagnosed PD patients
who had been initiated on PD therapy (Appendix 3). The mean
age is 73.4 years. Of the six medication categories, L-dopa was
the most common first line therapy (80.6%), followed by non-
ergot DAs (12.9%) and MAO-B inhibitors (7.9%) (Table 1). A very
low prescription rate for medications from the ergot DAs categoryTable 1
Characteristics of the study cohort.




Dopamine Agonists (DAs) 1291 (14.10%)
Levodopa 7366 (80.60%)
levodopa plus carbidopa or benserazide 7287 (79.70%)
levodopa plus carbidopa plus entacapone 79 (0.86%)
MAO-B inhibitors 719 (7.90%)
Number of patients on combination
therapy
963 (10.53%)
Age, mean (years) 73.4 years
40–60 years 845 (9.24%)
61–80 years 5670 (62.02%)




Welsh Index of Multiple deprivation (WIMD) quintile




5 (least deprived areas) 2086 (22.82%)
Health board
Swansea Bay University Health 2128 (23.28%)
Aneurin Bevan 1408 (15.40%)
Betsi Cadwaladr 2005 (21.93%)
Cardiff & Vale 1275 (13.95%)
Cwm Taf 845 (9.24%)
Hywel Dda 1158 (12.67%)
Powys** 323 (3.53%)






Pulmonary disease 510 (5.58%)
Cerebral vascular accident 338 (3.70%)
Acute myocardial infarction 321 (3.51%)
Dementia 255 (2.79%)
Congestive heart failure 192 (2.10%)
Renal disease 160 (1.75%)
Cancer 156 (1.71%)
Peripheral vascular disease 105 (1.15%)
Connective tissue disorder 90 (0.98%)
Paraplegia 74 (0.81%)
Diabetes complications 58 (0.63%)
Peptic ulcer 41 (0.45%)
Metastatic cancer 31 (0.34%)
Liver disease 10 (0.11%)
Severe liver disease 5 (0.05%)
Antidepressants
Previous use of antidepressants 2076 (22.70%)
* The total percentage exceeds 100% because patients can be on more than one
medication.
** Powys is unusual in that there are no acute hospitals there and that many
patients would go to England for treatment.
208was seen throughout the study (no more than 3.96%). For other
characteristics of the study cohort among different treatment
groups, see Table 1.
3.1. Logistic regression to identify factors that correlate with
prescribing of first line therapy
 Anticholinergics model
As shown in Table 2, age, sex, WIMD quintiles, year of prescrib-
ing, and dementia had significant effects on the odds of prescribing
anticholinergics as a first therapy. Compared to the younger
patients (40–60 years), older patients (61–80 and >80 years) were
38.4% and 70.3% less likely, respectively, to be prescribed anti-
cholinergics (p-value = 0.003 and <0.0001 respectively). Females
were 32.2% more likely to be prescribed anticholinergics (p-
value = 0.016). Patients who lived in the least deprived WIMD
quintile area were 45% less likely to be prescribed anticholinergics
compared to patients from the most deprived quintile area (p-val
ue < 0.0001) (see Fig. 2). The odds of prescription of anticholiner-
gics had significantly declined in the 2012–2016 period compared
to the 2000–2005 period (p-value < 0.0001) (Fig. 1). Patients with
dementia had higher odds of being prescribed anticholinergics (p-
value = 0.001) (Table 2).
 DAs model
In the DAs’ model, five factors were shown to have a significant
effect on the prescription of DAs. Older patients (61–80 and
>80 years) were 71.3% and 93.4% less likely, respectively, to be
prescribed DAs (p-value < 0.0001 for both). Compared to the
2000–2005 period, the odds of being prescribed DAs declined
significantly in the 2012–2016 period (p-value < 0.0001) (Fig. 1).
Diabetic and dementia patients were 46.5% and 51.5% less likely,
respectively, to be prescribed medicines from the DAs’ group
(p-value < 0.0001 and 0.023 respectively) (Table 2). Patients who
used antidepressants within one year before PD diagnosis were
15.9% less likely to be prescribed DAs (p-value = 0.029).
 Ergots DAs model
Table 2 shows that only two factors were shown to have a
significant effect on the prescription of ergot DAs. Older patients
(61–80 and >80 years) were less likely to be prescribed ergot
DAs compared to patients in the 40–60 year group
(p-value = 0.004 and <0.0001 respectively). Patients with previous
use of antidepressants also had less chance of being prescribed
ergot DAs (p-value = 0.036) (Table 2).
 Non-ergots DAs
Table 2 shows that the outcomes of this model were largely
similar to those reported in the DAs model. However, some differ-
ences were noticed. Unlike DAs, the prescription of non-ergot DAs
rose significantly by 35.3% in the period 2006–2011, and then sig-
nificantly declined in 2012–2016 by 64.7% (Fig. 1). The other differ-
ence was that there were no significant effects of dementia and
previous use of antidepressants in this model (Table 2).
 L-dopa model
Table 2 shows that age was a significant factor in the model.
Compared to the younger patients (40–60 years), older patients
(61–80 and >80 years) were around 3 and 19 times more likely,
respectively, to be prescribed medicines from the L-dopa category
(p-value < 0.0001 for both). There was no significant difference
between males and females in the prescription of medicines from
Table 2
- A series of multivariate logistic regression to predict prescribing of PD medications in the newly diagnosed PD patients.
Anticholinergics DAs Ergot DAs Non-ergot DAs Levodopa MAO-B inhibitors
Independent variable OR** 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Age categories 40–60 years (Ref)
61–80 years 0.61 0.44–0.84 0.28 0.24–0.33 0.50 0.31–0.80 0.28 0.24–0.33 4.00 3.43–4.66 0.48 0.39–0.59
> 80 years 0.29 0.19–0.44 0.06 0.05–0.08 0.13 0.06–0.28 0.06 0.05–0.08 19.17 15.72–24.72 0.14 0.11–0.20
Sex Males (Ref)
Females 1.32 1.05–1.65 – – – – – – 0.94 0.84–1.06 0.85 0.72–1.01
Social deprivation score (WIMD) 1 (most deprived areas) (Ref)
2 0.63 0.45–0.88 – – – – – – 0.93 0.77–1.13 1.35 1.00–1.83
3 0.47 0.33–0.66 – – – – – – 0.88 0.73–1.06 1.40 1.05–1.87
4 0.53 0.37–0.76 – – – – – – 0.80 0.66–0.97 1.69 1.26–2.25
5 (least deprived areas) 0.55 0.39–0.76 – – – – – – 0.77 0.65–0.93 1.98 1.51–2.61
Year of prescribing categories 2000–2005 (Ref)
2006–2011 0.37 0.28–0.49 0.99 0.86–1.14 – – 1.35 1.16–1.57 0.87 0.76–0.99 2.26 1.80–2.83
2012–2016 0.32 0.24–0.43 0.43 0.36–0.50 – – 0.59 0.50–0.71 1.91 1.65–2.21 2.44 1.95–3.06
Diabetes – – 0.53 0.38–0.75 – – 0.56 0.40–0.79 1.37 1.04–1.82 0.51 0.32–0.80
Pulmonary disease – – 0.89 0.64–1.23 – – 0.90 0.64–1.25 1.05 0.79–1.40 0.60 0.37–0.97
Cerebral vascular accident 0.56 0.25–1.22 0.67 0.41–1.09 – – 0.68 0.41–1.13 1.45 0.89–2.33 – –
Acute myocardial infarction – – 0.90 0.58–1.41 – – 0.97 0.62–1.51 1.22 0.82–1.82 0.58 0.30–1.12
Dementia 2.45 1.44–4.16 0.48 0.26–0.90 – – 0.55 0.29–1.03 1.43 0.88–2.31 – –
Congestive heart failure – – 0.68 0.34–1.32 – – 0.65 0.32–1.32 2.06 1.06–3.99 0.76 0.33–1.76
Renal disease – – 1.01 0.51–2.00 – – 0.91 0.44–1.87 1.68 0.82–3.43 – –
Cancer – – 0.85 0.46–1.59 – – 0.84 0.44–1.61 0.84 0.50–1.40 0.60 0.24–1.48
Peripheral vascular disease – – 0.98 0.45–2.11 – – 1.03 0.48–2.22 1.15 0.57–2.33 – –
Connective tissue disorder – – – – – – – – 1.99 0.84–4.71 – –
Paraplegia – – – – – – – – 10.06 1.31–77.22 – –
Diabetes complications – – – – – – – – 3.23 0.76–13.67 – –
Metastatic cancer – – – – – – – – 1.90 0.53–6.75 – –
Previous use of antidepressants 1.14 0.88–1.48 0.84 0.72–0.98 0.56 0.33–0.96 0.86 0.74–1.01 1.33 1.15–1.53 0.40 0.31–0.52
DAs, Dopamine Agonists; MAO-B, Monoamine Oxidase B; OR, Odd ratio; CI, Confidence interval; Ref, Reference; WIMD, Welsh Index of Multiple Deprivation.
**The significant OR is in bold.


















Fig. 1. Changes in the pattern of initial therapy prescribed to PD patients over time (medication categories).
Fig. 2. Prescribing percentage of PD medications stratified by social deprivation (WIMD quintile). WIMD, Welsh Index of Multiple Deprivation; COMT, Catechol-O-
methyltransferase; DAs, Dopamine Agonists; MAO-B, Monoamine Oxidase-B.
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WIMD quintile areas were 22.1% less likely to be prescribed
L-dopa compared to patients from the most deprived quintile area
(p-value = 0.007). Newly diagnosed PD patients in the 2012–2016
period were 91.3%more likely to be prescribed L-dopa compared to
newly diagnosed PD patients in the 2000–2005 period (p-value < 0.
0001) (Fig. 1). None of the comorbidities had a significant effect on
the prescription of medicines from the L-dopa category except for
diabetes, congestive heart failure, and paraplegia. Patients with
these conditions were significantly more likely to be prescribed
L-dopa. Patients with previous use of antidepressants were 33.3%
more likely to be prescribed L-dopa (see Table 2).210 MAO-B inhibitors model
Table 2 shows that patients aged 61–80 and >80 years were
51.5% and 85.1% less likely to be prescribed MAO-B inhibitors (p-
value < 0.0001 for both). There was no significant difference
between males and females in the prescription of MAO-B inhibi-
tors. Patients who lived in the least deprived WIMD quintile area
were 98.8% more likely to be prescribed MAO-B inhibitors com-
pared to patients in the most deprived quintile area (p-value < 0.
0001) . PD patients were around 1.4 times more likely to be pre-
scribed MAO-B inhibitors in the 2012–2016 period compared to
patients in the 2000–2005 period (p-value < 0.0001). No apparent
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2011 was seen (Fig. 1). Patients with diabetes or pulmonary
diseases were less likely to be prescribed MAO-B inhibitors
(p-value = 0.004 and 0.041 respectively). A previous use of antide-
pressants also had a significant effect on the prescription of MAO-B
(p-value < 0.0001) (Table 2).3.2. The sensitivity analysis
The outcomes of the sensitivity analysis were consistent after
excluding dementia patients (Appendix (4) in Supplementary
Data).4. Discussion
This purpose of this study is to examine the trends in first line
therapy for PD patients in Wales, over the period 2000–2016. The
analysis examined 9142 patients who were prescribed antiparkin-
sonian medications after the first diagnosis of PD. Between 2000
and 2016, there were significant changes in Wales in the initiation
of antiparkinsonian medications in PD. These changes were most
likely due to emerging evidence on the efficacy and safety of PD
medications.
Overall, L-dopa was the most common first therapy prescribed
(80.6% of patients); a similar pattern is reported in other countries
such as the USA, Japan, and Taiwan (Huse et al., 2006;
Swarztrauber et al., 2006; Guo et al., 2014; Nakaoka et al., 2014).
A previous UK study showed a lower rate of L-dopa prescribing
when used as an initial therapy, either as monotherapy or in com-
bination (46.5%) (Kalilani et al., 2019). There was no obvious rea-
son that explained this huge difference in L-dopa prescribing
rate. However, the method of identifying PD patients and medica-
tions in the CPRD study may be not the same as ours (Kalilani et al.,
2019). Nevertheless, this assumption cannot be confirmed since
the exact method of identifying patient and medications in CPRD
study was not clear. Additionally, there was no stratification by
patient characteristics in the CPRD study (Institute, 2017).
Over the study period (2000–2016), the trends in first therapy
underwent a significant switch towards L-dopa (particularly after
2010) in all PD patients, irrespective of age at presentation. Whilst
there have been no reported studies after 2010 that have examined
the trend of prescribing L-dopa as a first therapy across years, sev-
eral studies have shown a general increase in L-dopa prescribing
prior to 2010 for all stages of PD, i.e. both as an initiation therapy
and after progression of PD (Hollingworth et al., 2011; Pitcher
et al., 2014). It is well documented in some studies that many PD
patients who were initiated on DAs or MAO-B inhibitors were aug-
mented with or switched to L-dopa after 5 years from the original
therapy (Olanow et al., 2001).
In contrast to other studies, this study has demonstrated a sig-
nificant move away from prescribing non-ergot DAs, starting in
2010 in Wales. Of note, this was the year of publication of the
results of the DOMINION study which found that impulse control
disorders (ICDs) are significantly associated with DA usage
(Weintraub et al., 2010). Furthermore, other safety concerns
related to DAs were identified around 2010, including the risk of
heart failure that is associated with pramipexole usage (Mokhles
et al., 2012). This might go some way to explain the shift from pre-
scribing of DAs as first therapy to prescribing L-dopa which is more
effective and has less significant side effects (Olanow and Stocchi,
2017). A similar trend was noticed in other studies carried out in
the USA, where the prescription rate of non-ergot DAs decreased
by 5% between 2008 and 2011. This trend was for all PD patients,
regardless of whether or not they were newly diagnosed (Crispo
et al., 2015). This current study also found that the tendency to211prefer L-dopa as a first line therapy continued after the publication
of the PD-MED study in 2014 (Guo et al., 2014) which showed that
early initiation of L-dopa resulted in better long term QoL com-
pared to DAs andMAO-B inhibitors. With respect to the prescribing
of ergot DAs, it may be inferred from the results of this study that
the cardiotoxicity issues associated with pergolide (Yamamoto
et al., 2006) had a significant impact on its rate of prescribing
(Fig. 1). In accordance with these safety issues, no single ergot
DA was prescribed as a first line therapy in the period 2012–
2016. Although Kalilani et al. reported a 10% of ergot DAs use as
a first line therapy in UK between 2004 and 2015, they did not
stratify by year of prescribing (Kalilani et al., 2019); and therefore,
it is not possible to examine the effect of ergot DA safety literature
on prescribing in their study.
The general prescribing rate of MAO-B inhibitors increased sig-
nificantly in Wales, following the approval of rasagiline in 2006.
This trend has also been described in the USA and Finland
(Crispo et al., 2015; Keränen and Virta, 2016). There was no appar-
ent increase in MAO-B inhibitors in 2012–2016 compared to 2006–
2011 (Fig. 1). This could be for two reasons. Firstly, the fact that the
neuroprotective properties suggested by a range of clinical trials
such as TEMPO trial (Hauser et al., 2009), is negated by some
guidelines (Schapira, 2011); and, second, the results of the PD-
MED study that confirmed the inferiority of MAO-B inhibitors to
L-dopa in terms of long term QoL when treating early symptoms
of PD (Guo et al., 2014).
L-dopa was the predominant first drug prescribed in all Parkin-
son’s patients regardless of age. However, age was a significant
predictor of the first prescribed agent in all of the study models.
In general, younger patients (40–60 years) were more likely to be
prescribed DAs, MAO-B inhibitors, and anticholinergics. Older
adults (60–80 and >80 years), in contrast, were more likely to be
prescribed L-dopa. The tendency to prescribe L-dopa to older
adults and refrain from prescribing DAs has been similarly
reported in other studies (Swarztrauber et al., 2006; Keränen and
Virta, 2016; Fayard et al., 2011) and is in line with a variety of
guidelines that recommend refraining from prescribing DAs and
anticholinergics to older adults due to the risk of medicines related
harm (particularly cognitive side effects) (Olanow et al., 2001).
There is an interesting association between social deprivation
score and the prescribing of L-dopa and MAO-B inhibitors. No pre-
vious UK studies have measured or found such an association;
however, in the USA, some studies have found that more expensive
drugs, such as some DAs and MAO-B inhibitors, were more com-
monly prescribed to patients with a higher socioeconomic status
(Goudreau et al., 2016; Orayj and Lane, 2019). In Wales, prescrip-
tions have been free of charge since 2007, so the economic status
of the patients should not be an issue. A possible interpretation
of this finding is the significant delay in PD diagnosis in some
minority groups which has been reported outside the UK
(Dahodwala et al., 2011). Given that MAO-B inhibitors are often
used as a starter drug, individuals with a lower socioeconomic sta-
tus may be diagnosed at a later disease stage, in which case the
decision may be made to commence with L-dopa as the more effec-
tive therapy and therefore skip the MAO-B inhibitors step.
The positive association between diabetes and L-dopa prescrib-
ing identified in this study is strengthened by a negative associa-
tion between diabetes and DA and MAO-B inhibitor prescribing.
This may be multifactorial. Some studies report that newly diag-
nosed PD patients who have diabetes prior to the PD diagnosis tend
to have more severe motor symptoms (Cereda et al., 2012). Given
that as diabetes rates are linked to social deprivation indices this
could explain the association, but more work should be done to
determine exactly what this relationship is.
This was the first study to present a detailed description of the
factors associated with the prescription trends of antiparkinsonian
K. Orayj, A. Akbari, A. Lacey et al. Saudi Pharmaceutical Journal 29 (2021) 206–212medications in newly diagnosed PD patients in Wales. Moreover, it
was the first study to examine changes in first line therapy in PD
patients following the publication of the PD-MED study in 2014.
To ensure that a newly diagnosed cohort was identified, several
robust exclusion criteria were applied (such as excluding possible
drug-induced Parkinsonism cases and possible prevalent cases).
Sensitivity analyses showed a high degree of robustness in the
study results. Although there were no available data regarding
the severity of PD, this bias has been minimised by limiting the
study to newly diagnosed PD patients.
This study, however, is not without limitations. The date of the
first diagnosis was defined as the first diagnostic code of PD in SAIL,
but this may not show the true date of diagnosis. Other limitations
in this study are lack of PD clinical data; lack of dispensing data;
and the presence of unmeasured confounders, such as patients’
QOL, patient and physician preferences, and the subtype and sever-
ity of the PD. These limitations could be threats to internal validity
whereby unmeasured confounders may lead to a wrong assump-
tion of causal relationship in observational studies.
To conclude, this study provides a large and representative
sample of newly diagnosed PD patients in Wales, generalisable
across the UK due to highly comparative practise. The results indi-
cate a reasonable level of awareness of efficacy and safety concerns
related to PD medications that have evolved over the last 17 years
and alignment with contemporary guidance. Importantly, there is
evidence here of differences in prescribing, based not only on
age, but on social deprivation indices and comorbidities which
require further interrogation.
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